Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nickolas Stabellini

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|March 8, 2021
Sex Differences in Time to Treat and Outcomes for GliomasNickolas Stabellini, Halle Krebs, Nirav Patil, et al.
Cancer Medicine|September 28, 2023
Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
The Journal of Surgical Research|January 19, 2023
Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual DiseaseLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
Cancer|April 1, 2022
A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysisLifen Cao, Christopher W Towe, Robert Shenk, et al.
Frontiers in Oncology|May 11, 2023
Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
Current Problems in Cancer|July 10, 2026
Genomic risk distribution, adjuvant chemotherapy trends, and survival outcomes in women with pT1, grade 1-2, ER/PR-positive, LVI-negative breast cancerNickolas Stabellini, Maya Lubarsky, Ananya Munjal, et al.
Jornal Vascular Brasileiro|May 6, 2022
Temporal trends in vena cava filter implantation in public health system inpatients: an 11-year analysis of the largest city in BrazilDafne Braga Diamante Leiderman, Marcelo Fiorelli, Marcelo Passos Teivelis, et al.
Breast Cancer Research and Treatment|October 16, 2021
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysisLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
Breast Cancer Research and Treatment|January 20, 2026
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort studyNickolas Stabellini, Jasskiran Kaur, Cynthia Owusu, et al.
HIV Medicine|September 30, 2023
Heterogeneities of the impact of public health policies on HIV/AIDS indicators in Brazil according to sociodemographic factors: A real-life studyJulie V Sudovec-Somogyi, Felipe Krakauer, Alexandre A Ferreira, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|March 8, 2021
Sex Differences in Time to Treat and Outcomes for GliomasNickolas Stabellini, Halle Krebs, Nirav Patil, et al.
Cancer Medicine|September 28, 2023
Estimating the overall survival benefit of adjuvant chemo-endocrine therapy in women over age 50 with pT1-2N0 early stage breast cancer and 21-gene recurrence score ≥26: A National Cancer Database analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
The Journal of Surgical Research|January 19, 2023
Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual DiseaseLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
Cancer|April 1, 2022
A comparison of local therapy alone with local plus systemic therapy for stage I pT1aN0M0 HER2+ breast cancer: A National Cancer Database analysisLifen Cao, Christopher W Towe, Robert Shenk, et al.
Frontiers in Oncology|May 11, 2023
Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+/HER2- breast cancer pts with 1-3 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysisNickolas Stabellini, Lifen Cao, Christopher W Towe, et al.
Current Problems in Cancer|July 10, 2026
Genomic risk distribution, adjuvant chemotherapy trends, and survival outcomes in women with pT1, grade 1-2, ER/PR-positive, LVI-negative breast cancerNickolas Stabellini, Maya Lubarsky, Ananya Munjal, et al.
Jornal Vascular Brasileiro|May 6, 2022
Temporal trends in vena cava filter implantation in public health system inpatients: an 11-year analysis of the largest city in BrazilDafne Braga Diamante Leiderman, Marcelo Fiorelli, Marcelo Passos Teivelis, et al.
Breast Cancer Research and Treatment|October 16, 2021
Adjuvant trastuzumab with or without chemotherapy in stage 1 pT1N0 HER2+ breast cancer: a National Cancer Database analysisLifen Cao, Robert Shenk, Nickolas Stabellini, et al.
Breast Cancer Research and Treatment|January 20, 2026
Real-world outcomes of reduced-dose versus standard-dose antibody drug conjugates in metastatic breast cancer: a retrospective cohort studyNickolas Stabellini, Jasskiran Kaur, Cynthia Owusu, et al.
HIV Medicine|September 30, 2023
Heterogeneities of the impact of public health policies on HIV/AIDS indicators in Brazil according to sociodemographic factors: A real-life studyJulie V Sudovec-Somogyi, Felipe Krakauer, Alexandre A Ferreira, et al.
Pageof 5